IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Congress Wealth Management LLC DE

Congress Wealth Management LLC DE lowered its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 9.8% in the 4th quarter, Holdings Channel.com reports. The fund owned 1,073 shares of the company’s stock after selling 116 shares during the quarter. Congress Wealth Management LLC DE’s holdings in IDEXX Laboratories were worth $444,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the business. FSA Wealth Management LLC purchased a new stake in IDEXX Laboratories during the 3rd quarter worth $25,000. Rialto Wealth Management LLC acquired a new position in shares of IDEXX Laboratories during the fourth quarter worth about $30,000. Retirement Wealth Solutions LLC purchased a new stake in shares of IDEXX Laboratories in the fourth quarter worth about $31,000. Kestra Investment Management LLC acquired a new stake in shares of IDEXX Laboratories in the fourth quarter valued at about $38,000. Finally, Crews Bank & Trust purchased a new stake in shares of IDEXX Laboratories during the 4th quarter valued at about $41,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $415.87 on Friday. The stock has a market capitalization of $33.71 billion, a price-to-earnings ratio of 38.98, a PEG ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $548.88. The company’s 50-day simple moving average is $437.07 and its 200-day simple moving average is $443.27. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31.

Insiders Place Their Bets

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the transaction, the director now directly owns 3,061 shares of the company’s stock, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research firms have weighed in on IDXX. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Tuesday. Piper Sandler upped their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research note on Monday, February 10th. Bank of America lifted their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. Barclays upped their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. Finally, Morgan Stanley dropped their target price on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $533.75.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.